A few days later, while Yang Ping was in the laboratory, Manstein called with an urgent tone.
"Professor! Have you seen the news? Berg! Hansberg has been formally charged!"
Yang Ping imdiately put on speakerphone so the team could hear.
"The German prosecution just issued a statent, charging Professor Berg with multiple offenses including ’fraudulent dical practices causing severe bodily harm,’ ’comrcial fraud,’ and ’intellectual property infringent.’ The evidence includes his email exchanges, financial records with illegal institutions from the Three Kingdoms, and the complete dical and legal docunts of those three imitation therapy victims. The police also searched his laboratory and residence, uncovering more evidence. If found guilty, he could face over ten years in prison."
Manstein’s voice was complex, with both pain and relief: "The scientific community is in an uproar, but there’s more silence. He brought this upon himself. It serves as a warning to everyone."
Yang Ping paused for a mont and asked, "How did he react?"
"He reportedly refused to plead guilty, claiming it was just ’academic disagreent’ and ’normal industry consultation.’ But his legal team doesn’t seem optimistic."
After hanging up, the eting room fell silent.
Berg’s downfall marked the complete eradication of the most extre and unscrupulous faction resisting the old forces. It was a victory for law and scientific ethics. It cruelly announced that attempts to impede scientific progress through fraud and harm would ultimately pay a painful price.
"This will make others who are still hesitant or secretly sabotaging think twice," Tang Shun said.
Lu Xiaolu nodded, "Indeed, the door to cooperation is wide open, but the bottom line of the law is there too; it’s the best warning."
After several rounds of intense negotiations, the final draft of the "Sanbo Research Institute - Giant Group Global Strategy Cooperation Frawork on Systemic dicine" was completed with the joint efforts of legal teams and experts from both sides.
This 120-page docunt is filled with rigorous legal terminology and complex structural designs, but its core spirit remains firmly anchored in the initial consensus of the negotiations.
The signing ceremony of the morandum of understanding was not grand, it was only announced through the official websites and major academic journals of both parties, along with a summary version of the morandum.
Even so, it still caused a huge sensation in the global dical, industrial, and investnt communities.
Science magazine comnted, "This is the establishnt of a new dical model; this morandum could mark the dawn of a new era in academia-industry-research relationships: scientific creativity is placed at the absolute core, with capital playing a supporting and service role. If successful, it will beco a model for transformative technology translation in the future."
Bloomberg analyzed from a business perspective, "Giant’s gamble," "Li Gaoyang is staking his personal reputation and the company’s future on a science and technology that is not yet fully mature. If successful, Giant will be reborn and lead a new era; if failed, it could be abandoned by both new and old parties."
"A victory for the patients." Patient rights organizations cheered, viewing the emphasis in the morandum on patient data rights and benefit reciprocity as a milestone progress.
Other pharmaceutical companies, after initial shock, jealousy, and observation, finally began taking substantive action.
Companies like Novartis and Roche sent high-level delegations to the Nandu Sanbo Research Institute, seeking "similar cooperation opportunities tailored to their characteristics." The terms they brought were increasingly generous, and their posture increasingly humble.
Yang Ping had long entrusted the comrcialization of all research achievents of the Sanbo Research Institute to the Ruixing Pharmaceutical Group, focusing his team on research.
Outside the Sanbo Research Institute, traffic flowed as usual. There were no dia entourages besieging with long lenses, no noisy influencers, and not even many strange visitors wandering in the lobby; everything was orderly.
At this mont, in the top-floor eting room of the Ruixing Building.
On one side of the long conference table sat Ruixing dical’s founder and CEO, Huang Jiacai, along with his core team—including the chief strategy officer, chief scientific officer, international business president, and chief intellectual property legal counsel.
On the other side was Jas Collins, the senior vice president of global business developnt at Novartis, and his team. Collins, in his fifties, had neatly combed gray hair and exhibited the precision and restraint characteristic of the Swiss. Behind him followed business, legal, and technical evaluation commissioners.
"Mr. Collins, welco once again to Nandu," Huang Jiacai began, speaking standard Mandarin with a slight southern accent, his tone neither urgent nor slow, "We have carefully studied your preliminary intention for cooperation on the authorization of systemic regulation therapy in the European market. Ruixing and Sanbo Research Institute are in a deep strategic partnership, fully responsible for the comrcialization of all research outputs from Professor Yang Ping’s team. Therefore, any comrcial discussions can be conducted directly and efficiently between us."
Collins nodded slightly, "Mr. Huang, we appreciate your directness. Novartis has great interest and respect for systemic regulation theory, especially its remarkable application in the tumor field with K Therapy. We hope to explore an exclusive regional licensing model covering the European Union and Swiss markets."
Behind Huang Jiacai, the chief strategy officer, a capable woman, tapped her tablet lightly. The high-definition screen on the side of the eting room lit up, showing not a simple PPT but a dynamic, multi-layered visual model, with the "Sanbo Core" at the center and layers of collaboration circles unfolding around it.
User Comments
0 comments from readers